AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06612944
Drug: Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 AZA + BCL2 Inhibitor (Preferred Regimen) Subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; BCL2 inhibitor (VEN): 400 mg per day orally for one week (if combined with a CYP450 inhibitor, reduce to 100 mg per day).~1.2 AZA (DEC) + DLI For patients with TP53 mutations or those who do not respond to VEN, subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; decitabine at 5 mg/m² per day for 5 consecutive days, with a 28-day cycle (preferred for those with TP53 mutations). For patients without the option for DLI, regimen 1.1 is recommended.~DLI: Begins 3 months post-transplantation, starting with a dose of 1×10\^5 CD3+ T lymphocytes for haploidentical transplants, with doses increasing every 4-6 weeks to 5×10\^5 CD3+ T lymphocytes, 1×10\^6 CD3+, and 5×10\^6 CD3+ T lymphocytes; for full-matched transplants, the starting dose is 5×10\^5 CD3+ T lymphocytes with dose escalations as above to 1×1
Trial: NCT05728229
Drug: Supplement with SiderAl® Med
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation with special purpose food
Trial: NCT05029882
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05019326
Drug: Andrographis Paniculata
RxNorm normalized name: Andrographis paniculata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
Trial: NCT05019326
Drug: Boesenbergia
RxNorm normalized name: BOESENBERGIA ROTUNDA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
Trial: NCT04968002
Drug: pablizumab combined with apatinib and neoadjuvant chemotherapy
RxNorm normalized name: picodralazine and diuretics, combinations with psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients with stage IIa-IIIa non-small cell lung cancer are treated with pablizumab combined with apatinib and neoadjuvant chemotherapy
Trial: NCT05400317
Drug: AD-218A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 12weeks
Trial: NCT06155903
Drug: Anesthesiological mixtures (Spinal anesthesia)
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg.
Trial: NCT06155903
Drug: Anesthesiological mixtures (Peripheral nerve block)
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
Trial: NCT05854667
Drug: Treatment as Usual plus Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
Trial: NCT05854667
Drug: Treatment as Usual plus Placebo plus Contingency Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
Trial: NCT06191991
Drug: ALG-055009
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg
Trial: NCT06191991
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg
Trial: NCT04140721
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill identical to moxonidine administered for 4 weeks
Trial: NCT05249556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for ganaxolone)
Trial: NCT05844462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo
Trial: NCT05951777
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Saline Solution 0.9%
Trial: NCT04941989
Drug: HTL0022562
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0022562
Trial: NCT04941989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05994742
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin is a macrolide antibiotic, and is approved for use in children by the FDA (ID: 3263750) and EMA (EMA/2872/2021).
Trial: NCT05994742
Drug: Pyridoxine Hydrochloride
RxNorm normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine is a form of vitamin B6 used to prevent peripheral neuropathy among children receiving isoniazid.
Trial: NCT04975516
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given chemotherapy
Trial: NCT05728658
Drug: ICP-248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
Trial: NCT04667663
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
Trial: NCT06101745
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Phase 3A only, 50 subjects will be randomly allocated to receive sugar placebo
Trial: NCT04969835
Drug: AVA6000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVA6000 is a FAP-activated doxorubicin.
Trial: NCT05751967
Drug: Placebo Combined With Ursodeoxycholic Acid
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet/ day
Trial: NCT05751967
Drug: Fenofibrate Combined With Ursodeoxycholic Acid
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day
Trial: NCT05853601
Drug: Single Dose Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are given a single loading dose of theophylline, 5mg/kg IV, within 18 hours after birth. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
Trial: NCT05853601
Drug: Repeat Dose Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are given a loading dose of theophylline, 5mg/kg IV, within 18 hours of birth, and then two subsequent doses (1.2mg/kg iv) at 12 hours and 24 hours after loading dose. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
Trial: NCT06377566
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 25 mg/m\^2 IV
Trial: NCT05918861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets
Trial: NCT05639543
Drug: INT-787
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded Study Drug
Trial: NCT05639543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05555888
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Trial: NCT05863234
Drug: PPMX-T003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The therapeutic agent is administered continuously intravenously
Trial: NCT04495452
Drug: Fentanyl Drug Administration
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
Trial: NCT06191263
Drug: RVU120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Trial: NCT05840809
Drug: First line tuberculosis treatment
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study - the decision to use first-line tuberculosis treatment will have already been made by the responsible clinician. The study itself does not require any additional intervention.
Trial: NCT06324396
Drug: Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of pravastatin will be administered to all study subjects.
Trial: NCT06367283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
Trial: NCT04747912
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
Trial: NCT06473740
Drug: Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen)
RxNorm normalized name: deoxyribonucleases / plasmin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug Neovasculgen is a highly purified supercoiled form of the pCMV-VEGF165 plasmid, encoding the Vascular endothelial growth factor (VEGF) under the control of a promoter (DNA control region). Recombinant plasmid DNA consists of the following components: a fragment of the regulatory region (22 nucleotide pairs), which determines the transcription of the gene, the VEGF minigene, upon expression of which the VEGF isoform is synthesized, consisting of 165 amino acids, a splicing signal, a polyadenylation signal and the SV40 transcription terminator, ensuring the synthesis of the mature RNA gene and auxiliary regions required for efficient biosynthesis of plasmid DNA in the cells of the producer strain of Escherichia coli. When molecules of this plasmid penetrate into mammalian cells, VEGF is produced, which stimulates endothelial cells, which leads to the growth of blood vessels (vascularization) in the area of injection.
Trial: NCT04738123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsules
Trial: NCT05731726
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05731726
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celebrex
Trial: NCT00000912
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05870358
Drug: Melatonin 3 MG
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
Trial: NCT05978063
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo administered twice daily
Trial: NCT05737069
Drug: Ibuprofen arginine granules 400 mg
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
Trial: NCT05737069
Drug: Ibuprofen arginine granules 400 mg (Spedifen)
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
Trial: NCT06135805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of placebo oral gel on oral lesions
Trial: NCT05750264
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg of IV ibuprofen
Trial: NCT05978193
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years
Trial: NCT05978193
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles
Trial: NCT06273774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06596512
Drug: PARTICS using a single ICS add on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to PARTICS who use a nebulizer less than once a week are instructed to use the study prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.
Trial: NCT06595186
Drug: JK-1201I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JK-1201I will be administered.
Trial: NCT06594224
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.
Trial: NCT05548582
Drug: Acetaminophen 500 mg Tab
RxNorm normalized name: Acetaminophen 500 mg tablet for oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prescription
Trial: NCT05548582
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard prescription
Trial: NCT06412471
Drug: SSGJ-707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bispecific antibody
Trial: NCT06412471
Drug: PD-1/L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors
Trial: NCT06594822
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily
Trial: NCT06589219
Drug: CMR316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort
Trial: NCT05637086
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
Trial: NCT05637086
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
Trial: NCT06589219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration
Trial: NCT06590714
Drug: Experimental(Acelex cap m2mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Arm (Polmacoxib (Acelex cap 2mg + NSAIDs-excluded non-opioid or opioid analgesics))~Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.~NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
Trial: NCT05615948
Drug: VTS-K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary oral formulation of 486mg aspirin and 80mg ketamine
Trial: NCT06602557
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients included in the inhaled amikacin group will receive inhaled antibiotic therapy by nebulization of amikacin at a dose of 25 mg/kg in 1 daily dose (+/- 3 hours apart), within 6 hours of randomization and for a total duration of 5 days.
Trial: NCT06602557
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in the standard of care group will not receive any nebulization. They will receive Standard care alone.
Trial: NCT06594315
Drug: Deuterated Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT06601283
Drug: Vitmain C plus herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
Trial: NCT06591494
Drug: Classic quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Clarithromycin 500 mg BID
Trial: NCT06591494
Drug: Quadruple therapy with sodium bicarbonate instead of clarithromycin
RxNorm normalized name: Neut brand of sodium bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Sodium bicarbonate 500 mg TID
Trial: NCT05611281
Drug: GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage was calculated according to body weight and dose group once a day according to the assigned group.
Trial: NCT04984668
Drug: GT90001+KN046
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT90001 7.0mg/Kg， KN046 5mg/Kg
Trial: NCT04984668
Drug: GT90001+KN046
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT90001 7.0mg/Kg ， KN046 3mg/Kg
Trial: NCT04984668
Drug: GT90001/KN046
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT90001 4.5mg/Kg / KN046 5mg/Kg
Trial: NCT04984668
Drug: GT90001+KN046
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT90001 4.5mg/Kg， KN046 3mg/Kg
Trial: NCT04984668
Drug: GT90001+KN046
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT90001 3mg/Kg ， KN046 3mg/Kg
Trial: NCT00000827
Drug: Anti-HIV Immune Serum Globulin (Human)
RxNorm normalized name: immune globulin subcutaneous (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05345639
Drug: LRA Loco-regional anesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral parasternal block or transverse thoracic block are performed ultrasound-guided, at the end of surgery in the operating room. Once in the desired plane depending on the randomisation (transverse or parasternal), a volume of 20 ml of ropivacaine at 2 mg/ml is injected on each side of the sternum.~The intervention (TTP or PSB) is performed by the anesthetist-resuscitator investigator.
Trial: NCT04853069
Drug: Transdermal estradiol gel
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
Trial: NCT05239390
Drug: SCI -110
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis.
Trial: NCT06313567
Drug: Metronomic capecitabine group
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
Trial: NCT06128954
Drug: 900mg TETA 4HCl Once Daily Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x300mg trientine base tablets as a single AM dose
Trial: NCT06128954
Drug: 900mg TETA 4HCl Cuprior®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 x150mg trientine base tablets in two equally divided doses